FDA
-
-
-
-
-
-
-
NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial
-
-
-
-
-
-
-
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
-
-
-
-
-
-
-
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
-
-
335,529 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


